StatLab Medical Products Signs Definitive Agreement With Diapath
StatLab Medical Products (“StatLab”), a leading global developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has reached an agreement to acquire Diapath S.p.A. (“Diapath”), a prominent Italian manufacturer of histology and cytology products and equipment. The integration of Diapath, with its highly innovative equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, Middle East and Africa, and Latin America, positions StatLab to expand its market access, unlocking significant potential for growth and enhancing its global leadership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240828096902/en/
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. (Photo: Business Wire)
The transaction is expected to close during the third quarter of 2024, subject to regulatory approvals. Upon closing, Diapath founder Vladimiro Bergamini will transition to a senior advisor role at StatLab, and Chief Operating Officer Alberto Battistel will join StatLab’s executive leadership team and help steer the Diapath business unit as its Managing Director.
“This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow,” said Sung-Dae Hong, CEO of StatLab. “Our partnership with Diapath will provide an opportunity to expand their equipment brand throughout global markets, including the U.S. The combination will also enhance StatLab’s European market access for slides, cassettes, and printers, driving our product innovation and manufacturing excellence to the next level. I’m excited to welcome Alberto and the talented Diapath team to StatLab and continue to build upon the legacy Vladimiro and his family have developed over the past three decades.”
Headquartered in Martinengo, near Bergamo, Italy, Diapath was founded in 1997 by Vladimiro Bergamini. Over the past 27 years, focused investments have enabled the business to expand beyond consumables manufacturing and into the design, development, and production of a variety of core histology instruments.
Diapath’s equipment portfolio, which includes tissue processors, stainers, embedding centers, and microtomes, is underpinned by its innovative development process and cutting-edge Italian design and quality, resulting in a differentiated product set that resonates with customers. The Diapath Donatello automatic tissue processor won a prestigious A’Design Award for Scientific Instruments, and the T-Filler Automatic Formalin dispenser protects technicians from chemical exposure while ensuring specimens receive the correct ratio of formalin. In addition to their strong Italian presence, Diapath’s subsidiaries support focused growth of Diapath products to laboratories in Germany and France.
“The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs,” said Vladimiro Bergamini, CEO & President of Diapath. “Our combined company will be uniquely positioned to further expand Diapath’s brand and business, together transforming the anatomic pathology market through innovative development and manufacturing. I’m looking forward to the work my team will do with Dae and StatLab to leverage our combined global manufacturing capabilities to capture new business opportunities.”
About StatLab Medical Products
StatLab Medical Products has been dedicated to helping anatomic pathology laboratories provide the best possible patient care since 1976. We offer an extensive portfolio of self-manufactured consumables and labeling and tracking equipment from eight manufacturing sites in the United States, United Kingdom, and Germany. Our global operational footprint powered by over 600 mission-driven colleagues delivers a dependable and resilient supply chain of high-quality products and solutions, and a customer-centric approach inspires us to deliver reliability, innovation, and quality in every interaction. Learn more at StatLab.com.
About Diapath
Diapath is a leading Italian company specializing in the design, development, and manufacturing of advanced histology and cytology instruments and consumables. With nearly three decades of experience, Diapath is committed to innovation and excellence, offering cutting-edge solutions that redefine laboratory processes to ensure increasingly reliable diagnostics for better cancer care. Our products, distinguished by their Italian design and quality, range from processors and stainers to embedding centers and more, supporting the entire anatomic pathology workflow. Dedicated to enhancing histological research and diagnostics, Diapath continues to set industry standards with a focus on quality and innovation. Learn more at Diapath.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240828096902/en/
Contacts
Jessica Baer
jbaer@statlab.com
630-346-1659
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeiGene Announces Updates to Commercial Leadership Team9.9.2024 14:00:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. “We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “Matt’s management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies.” Mr. Shaulis is a global commercial executive with over 20 years of experience at biopharmaceutical companies such as Hansa Biopharma, Pfizer, Teva, Cephalon, and Johnson & Johnson. While at Pfizer, he directed the U.S. commercialization of blockbuster therapies IBRANCE® and XTANDI® as well as leading Pfizer’s acquisition and integration of Medivation. Mr
LuminUltra Acquires Legionella Testing Business from Genomadix and Inks Strategic License to Commercialize Additional Tests for Ultra-portable Molecular Diagnostic Platform9.9.2024 14:00:00 EEST | Press release
LuminUltra (luminultra.com), the global leader in applied molecular diagnostics, today announced the acquisition of the legionella testing business assets of Genomadix Inc (genomadix.com), along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets globally using the Genomadix Cube™ qPCR (quantitative polymerase chain reaction) Platform. With this transaction, LuminUltra further expands its industry-leading portfolio of molecular testing solutions for rapid identification and quantification of the microbes within residential, commercial and industrial water systems that are responsible for causing the potentially deadly Legionnaire’s disease. When paired with its easy-to-use automated test kit, the Genomadix Cube thermocycling platform will generate results that measure the presence and quantity of Legionella contamination in under one hour with laboratory-grade sensitivity. The elegant simplicity of the system allows an
Forrester’s 2025 Budget Planning Guides: Leaders Across Functions, Industries, And Geographies Intend To Spend More In 20259.9.2024 12:00:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2025 Budget Planning Guides, leaders intend to spend more in 2025 after a year of restrained budget expectations. Despite high interest rates, tight labour markets, and the uncertainty of US elections, 91% of global tech decision-makers and 87% of global marketing decision-makers are planning for budget increases in the year ahead. Pressure to optimise spending and drive efficiencies remains a focus for organisations, however. As a result, to derive the most value from increased budgets, leaders must invest in cross-functional efforts that have an outsized impact on their firm’s growth. Forrester’s Budget Planning Guides provide data-backed recommendations for technology and security, B2B and B2C marketing, customer experience (CX), digital strategy, and sales and revenue operations leaders to make sound planning and budgeting decisions for the coming year. The guides also include spending intention benchmarks and recommendations for areas to exp
New KPMG Report Shows Illicit Cigarette Consumption Still at Worrying Levels in the European Union, With Organized Crime Moving Operations Closer to Western Countries9.9.2024 11:00:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today warns about the high levels of contraband and counterfeit cigarettes in the European Union (EU) year over year, with 35.2 billion illicit cigarettes consumed in the region in 2023, accounting for 8.3% of total consumption in the EU, an increase of 0.1 percentage point compared to 2022. PMI praises European law enforcement agencies for their continued crackdown on criminal networks that profit from the illicit tobacco trade, and calls on regulators to advance a sensible, data-driven policy approach that puts consumers—and public health—front and center and that effectively addresses the challenges posed by the millions of adult smokers who are turning to the black market rather than quitting or, for those who do not quit, switching to smoke-free products. The results of the 2023 KPMG annual study on illicit cigarette consumption, commissioned by Philip Morris Products SA, revealed that the illicit market in the EU continues to be a
Top IP Executive Takes Leadership Position at Sisvel9.9.2024 10:08:00 EEST | Press release
Jukka Nihtilä has today joined Sisvel as head of the firm’s Business Development function. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240908679671/en/ Jukka Nihtilä, Head of Business Development, Sisvel (Photo: Business Wire) Previously Head of Business Development, Multimedia and New Segments at Nokia Technologies, Nihtilä is widely recognised as a major figure in the global patent transactions market and was recently named as one of the world’s leading IP strategists by IAM. Nihtilä will be working out of Sisvel’s Barcelona office with a broad remit to identify new business opportunities and turbocharge existing ones, while ensuring the firm can extract the most from the knowledge and skills of its highly talented team. “I am delighted to be joining Sisvel at such an exciting time,” he says. “The firm has a strong reputation for its flexible, innovative approaches to tackling the challenges posed by an increasingly com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom